Oxford Biomedica PLC Board Appointment (4527X)
26 Avril 2023 - 8:00AM
UK Regulatory
TIDMOXB
RNS Number : 4527X
Oxford Biomedica PLC
26 April 2023
Oxford Biomedica Appoints Leone Patterson as Non-Executive
Director
Oxford, UK - 26(th) April 2023: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Company"), a quality and innovation-led
viral vector CDMO, today announces the appointment of Ms Leone
Patterson as an Independent Non-Executive Director. Ms Patterson
shall join the Board on 1(st) May 2023.
Ms Patterson has more than 20 years of public company biotech
experience including in the cell and gene therapy industry and has
managed significant growth within international commercial
companies working across areas including strategy, finance,
operations and governance.
She is currently the Chief Financial and Business Officer at
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage company with a
mission to discover, develop, and deliver potentially curative
therapies, including gene therapy, for heart disease. Ms Patterson
also serves on the Board of Directors for Nkarta (NASDAQ:NKTX), a
clinical-stage cell therapy company. Previously, Ms Patterson held
leadership roles, including Chief Executive Officer and Chief
Financial Officer, at Adverum Biotechnologies, a gene therapy
company focused on rare and ocular diseases. She has also held the
role of Chief Financial Officer at public companies, including
diagnostics firm Diadexus and speciality pharmaceuticals provider
Transcept Pharmaceuticals and, earlier in her career, worked within
Novartis, Chiron and KPMG. She holds a B.S. in business
administration and accounting from Chapman University, an executive
M.B.A. from St. Mary's College, and is a Certified Public
Accountant (inactive).
Dr. Roch Doliveux, Chair of Oxford Biomedica, said: "The
appointment of Leone comes at an important juncture for Oxford
Biomedica, as we advance our global leadership in viral vector
development and supply, providing innovative solutions to our
international biopharma customers. Leone's deep understanding of
corporate finance, her experience of the US public markets and
M&A, in addition to her extensive experience in the cell and
gene therapy industry will be invaluable in supporting our
international strategy and further strengthening our market
position."
Ms Leone Patterson said: "I am honoured to be joining the Board
of Oxford Biomedica, a global innovation-led CDMO dedicated to
enabling the development of life-saving cell and gene therapies. I
look forward to working with the Board and contributing my
expertise to help advance the Company's strategy."
Diadexus voluntarily filed for Chapter 7 bankruptcy in June 2016
while Ms. Patterson was its Chief Financial Officer. Save as
disclosed, there are no other disclosures required to be made in
accordance with LR 9.6.13R.
-Ends-
Enquiries:
Oxford Biomedica plc:
Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488/ E:
ir@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394
562 425 / E: ir@oxb.com
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led
viral vector CDMO with a mission to enable its clients to deliver
life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and a US-based
subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US.
Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on
LinkedIn, Twitter and YouTube.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUAGCUPWPGA
(END) Dow Jones Newswires
April 26, 2023 02:00 ET (06:00 GMT)
Oxford Biomedica (AQSE:OXB.GB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Oxford Biomedica (AQSE:OXB.GB)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024